Standardizing methods for assessing omega-3 fatty acid biostatus

William Harris, Clemens von Schacky, Yongsoon Park

Research output: Chapter in Book/Report/Conference proceedingChapter

31 Citations (Scopus)

Abstract

The Omega-3 Index is the sum of EPA+DHA in RBC membranes expressed as a percent of total fatty acids. Typical levels range from 3% to 9%, with a US average value of between 5%-6%. The Index is a marker of tissue EPA+DHA and therefore reflects an individual's EPA+DHA status. The Omega-3 Index fulfills most of the criteria for a valid biomarker. In routine clinical practice, the Omega-3 Index can be used to assess baseline n-3 fatty acid status and to check for compliance with a recommendation to increase the n-3 fatty acid intake. In the research setting, the Omega-3 Index can likewise document compliance, both to confirm that those assigned to the n-3 fatty acid group followed instructions and that those assigned to placebo did not take n-3 fatty acid off protocol. In addition, the Omega-3 Index can be used as an inclusion criterion in trial design to confirm that only individuals most likely to benefit from n-3 fatty acid treatment are included. The widespread clinical implementation of the Omega-3 Index will allow clinicians to detect n-3 "insufficiency", to better stratify patients with respect to risk for disease, and it could ultimately contribute to a reduced burden of chronic disease.

Original languageEnglish (US)
Title of host publicationThe Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention
PublisherNova Science Publishers, Inc.
Pages385-398
Number of pages14
ISBN (Print)9781624177033
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Omega-3 Fatty Acids
Compliance
Chronic Disease
Fatty Acids
Biomarkers
Placebos
Membranes
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Harris, W., von Schacky, C., & Park, Y. (2013). Standardizing methods for assessing omega-3 fatty acid biostatus. In The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention (pp. 385-398). Nova Science Publishers, Inc..

Standardizing methods for assessing omega-3 fatty acid biostatus. / Harris, William; von Schacky, Clemens; Park, Yongsoon.

The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention. Nova Science Publishers, Inc., 2013. p. 385-398.

Research output: Chapter in Book/Report/Conference proceedingChapter

Harris, W, von Schacky, C & Park, Y 2013, Standardizing methods for assessing omega-3 fatty acid biostatus. in The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention. Nova Science Publishers, Inc., pp. 385-398.
Harris W, von Schacky C, Park Y. Standardizing methods for assessing omega-3 fatty acid biostatus. In The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention. Nova Science Publishers, Inc. 2013. p. 385-398
Harris, William ; von Schacky, Clemens ; Park, Yongsoon. / Standardizing methods for assessing omega-3 fatty acid biostatus. The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention. Nova Science Publishers, Inc., 2013. pp. 385-398
@inbook{b97f52011df7408f878de903b79ad9c8,
title = "Standardizing methods for assessing omega-3 fatty acid biostatus",
abstract = "The Omega-3 Index is the sum of EPA+DHA in RBC membranes expressed as a percent of total fatty acids. Typical levels range from 3{\%} to 9{\%}, with a US average value of between 5{\%}-6{\%}. The Index is a marker of tissue EPA+DHA and therefore reflects an individual's EPA+DHA status. The Omega-3 Index fulfills most of the criteria for a valid biomarker. In routine clinical practice, the Omega-3 Index can be used to assess baseline n-3 fatty acid status and to check for compliance with a recommendation to increase the n-3 fatty acid intake. In the research setting, the Omega-3 Index can likewise document compliance, both to confirm that those assigned to the n-3 fatty acid group followed instructions and that those assigned to placebo did not take n-3 fatty acid off protocol. In addition, the Omega-3 Index can be used as an inclusion criterion in trial design to confirm that only individuals most likely to benefit from n-3 fatty acid treatment are included. The widespread clinical implementation of the Omega-3 Index will allow clinicians to detect n-3 {"}insufficiency{"}, to better stratify patients with respect to risk for disease, and it could ultimately contribute to a reduced burden of chronic disease.",
author = "William Harris and {von Schacky}, Clemens and Yongsoon Park",
year = "2013",
month = "3",
language = "English (US)",
isbn = "9781624177033",
pages = "385--398",
booktitle = "The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Standardizing methods for assessing omega-3 fatty acid biostatus

AU - Harris, William

AU - von Schacky, Clemens

AU - Park, Yongsoon

PY - 2013/3

Y1 - 2013/3

N2 - The Omega-3 Index is the sum of EPA+DHA in RBC membranes expressed as a percent of total fatty acids. Typical levels range from 3% to 9%, with a US average value of between 5%-6%. The Index is a marker of tissue EPA+DHA and therefore reflects an individual's EPA+DHA status. The Omega-3 Index fulfills most of the criteria for a valid biomarker. In routine clinical practice, the Omega-3 Index can be used to assess baseline n-3 fatty acid status and to check for compliance with a recommendation to increase the n-3 fatty acid intake. In the research setting, the Omega-3 Index can likewise document compliance, both to confirm that those assigned to the n-3 fatty acid group followed instructions and that those assigned to placebo did not take n-3 fatty acid off protocol. In addition, the Omega-3 Index can be used as an inclusion criterion in trial design to confirm that only individuals most likely to benefit from n-3 fatty acid treatment are included. The widespread clinical implementation of the Omega-3 Index will allow clinicians to detect n-3 "insufficiency", to better stratify patients with respect to risk for disease, and it could ultimately contribute to a reduced burden of chronic disease.

AB - The Omega-3 Index is the sum of EPA+DHA in RBC membranes expressed as a percent of total fatty acids. Typical levels range from 3% to 9%, with a US average value of between 5%-6%. The Index is a marker of tissue EPA+DHA and therefore reflects an individual's EPA+DHA status. The Omega-3 Index fulfills most of the criteria for a valid biomarker. In routine clinical practice, the Omega-3 Index can be used to assess baseline n-3 fatty acid status and to check for compliance with a recommendation to increase the n-3 fatty acid intake. In the research setting, the Omega-3 Index can likewise document compliance, both to confirm that those assigned to the n-3 fatty acid group followed instructions and that those assigned to placebo did not take n-3 fatty acid off protocol. In addition, the Omega-3 Index can be used as an inclusion criterion in trial design to confirm that only individuals most likely to benefit from n-3 fatty acid treatment are included. The widespread clinical implementation of the Omega-3 Index will allow clinicians to detect n-3 "insufficiency", to better stratify patients with respect to risk for disease, and it could ultimately contribute to a reduced burden of chronic disease.

UR - http://www.scopus.com/inward/record.url?scp=84885020903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885020903&partnerID=8YFLogxK

M3 - Chapter

SN - 9781624177033

SP - 385

EP - 398

BT - The Omega-3 Fatty Acid Deficiency Syndrome: Opportunities for Disease Prevention

PB - Nova Science Publishers, Inc.

ER -